About: SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?
Creator	Ferro, Matteo Musi, Gennaro Palmer, Katie Porreca, Angelo Sciarra, Alessandro Busetto, Gian Giudice, Francesco Maggi, Martina Busetto, Colonna, Ascanio D'agostino, Daniele De Berardinis, Ettore De Cobelli, Ottavio Hurle, Rodolfo Lucarelli, Giuseppe Muto, Matteo Paliano, Di Romagnoli, Daniele Terracciano, Daniela
Source	Medline; PMC
abstract	BACKGROUND: The new severe acute respiratory syndrome virus (SARS-CoV-2) outbreak is a huge health, social and economic issue and has been declared a pandemic by the World Health Organization. Bladder cancer, on the contrary, is a well-known disease burdened by a high rate of affected patients and risk of recurrence, progression and death. SUMMARY: The coronavirus disease (COVID-19 or 2019-nCoV) often involves mild clinical symptoms but in some cases, it can lead to pneumonia with acute respiratory distress syndrome and multiorgan dysfunction. Factors associated with developing a more severe disease are increased age, obesity, smoking and chronic underlying comorbidities (including diabetes mellitus). High-risk non-muscle-invasive bladder cancer (NMIBC) progression and worse prognosis are also characterized by a higher incidence in patients with risk factors similar to COVID-19. Immune system response and inflammation have been found as a common hallmark of both diseases. Most severe cases of COVID-19 and high-risk NMIBC patients at higher recurrence and progression risk are characterized by innate and adaptive immune activation followed by inflammation and cytokine/chemokine storm (interleukin [IL]-2, IL-6, IL-8). Alterations in neutrophils, lymphocytes and platelets accompany the systemic inflammatory response to cancer and infections. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for example have been recognized as factors related to poor prognosis for many solid tumors, including bladder cancer, and their role has been found important even for the prognosis of SARS-CoV-2 infection. KEY MESSAGES: All these mechanisms should be further analyzed in order to find new therapeutic agents and new strategies to block infection and cancer progression. Further than commonly used therapies, controlling cytokine production and inflammatory response is a promising field.
has issue date	2020-06-09(xsd:dateTime)
bibo:doi	10.1159/000509065
bibo:pmid	32516772
has license	no-cc
sha1sum (hex)	45b1285060e9db4cba63383c4281212c5969517b
schema:url	https://doi.org/10.1159/000509065
resource representing a document's title	SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?
has PubMed Central identifier	PMC7316644
has PubMed identifier	32516772
schema:publication	Urol Int
resource representing a document's body	covid:45b1285060e9db4cba63383c4281212c5969517b#body_text
is schema:about of	named entity 'severe acute respiratory syndrome' named entity 'ISSUE' named entity 'IS A' named entity 'HIGH RATE' named entity 'PROGRESSION' named entity 'disease' named entity 'COVID-19' named entity 'Summary' named entity 'Features' named entity 'social and economic' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'Infection' named entity 'High-Risk' named entity 'ARDS' named entity 'receptor' named entity 'MERS-CoV' named entity 'China' named entity 'tumor microenvironment' named entity 'infection' named entity 'receptors, retinoic acid' named entity 'meta-analysis' named entity 'comorbidities' named entity 'transmembrane' named entity 'Neutrophils' named entity 'respiratory distress' named entity 'transurethral resection' named entity 'basophil' named entity 'prognosis' named entity 'multivariate analyses' named entity 'multivariate analysis' named entity 'molecular mechanisms' named entity 'immune response' named entity 'receptor' named entity 'COVID' named entity 'obesity' named entity 'carcinoma in situ' named entity 'adaptive immune' named entity 'monoclonal antibodies' named entity 'immunotherapy of cancer' named entity 'COVID-19 infection' named entity 'ICU' named entity 'SARS-CoV-2' named entity 'diabetes' named entity 'immunosenescence' named entity 'inflammation' named entity 'SARS-CoV-2' named entity 'tumor necrosis factor α' named entity 'risk factor' named entity 'lymphocyte' named entity 'Cytokines' named entity 'platelets' named entity 'IL-3' named entity 'Prognosis' named entity 'cardiovascular disease' named entity 'IL-10' named entity 'IL-6' named entity '2019-nCoV' named entity 'prognosis' named entity 'ACE2' named entity 'BCG' named entity 'infection' named entity 'precision medicine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software